Melissa S. A. M. Bevers
Research Subjects
Melissa S. A. M. Bevers has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Joop Pw van Den Bergh
Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands
3 shared publications - Bert van Rietbergen
Department of Biomedical Engineering, Orthopaedic Biomechanics Group, Eindhoven University of Technology, the Netherlands
2 shared publications - Caroline E. Wyers
Department of Internal Medicine, VieCuri Medical Center , 5912 BL Venlo
2 shared publications - Piet Geusens
Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, the Netherlands
2 shared publications Alfonso Dario Santamaria
Bioengineering and Computing Laboratory, IRCCS Istituto Ortopedico Rizzoli
1 shared publication- Ali Ghasem-Zadeh
Departments of Endocrinology and Medicine, Austin Health, The University of Melbourne , Melbourne, VIC 3084
1 shared publication
Latest Publications
- Open Access
- 20 February 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (4) , ziag025
Open and reproducible research in musculoskeletal imaging: Why it matters and how to implement it with the guidelines of the ORMIR community
The Open and Reproducible Musculoskeletal Imaging Research (ORMIR) community is a scientific community dedicated to promoting openness and reproducibility in musculoskeletal imaging, image processing, and computational modelling. In this perspective paper, we outline the motivations for conducting transparent research and provide practical guidelines to implement it. We start with defining open and reproducible research and describing the benefits and challenges of working transparently. Next, we redefine the outputs of a computational research study as—ideally—a combination of data, code, and a publication, recommend a folder and file structure that reflects these three study outcomes, and describe how to maintain and update such a structure during the study and at study publication. Finally, we emphasize that working in an open and reproducible manner is a learning process and the best way to acquire the necessary competencies is simply to start. Lay summary: The ORMIR community promotes openness and reproducibility in musculoskeletal imaging research. In this perspective paper, we explain why transparency matters and recommend how to conduct a computational study in an open and reproducible manner focusing on its three outputs: data, code, and publication. Finally, we highlight that the best way to learn these practices is simply to start.
- 20 February 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (4) , ziag025
Open AccessOpen and reproducible research in musculoskeletal imaging: Why it matters and how to implement it with the guidelines of the ORMIR community
The Open and Reproducible Musculoskeletal Imaging Research (ORMIR) community is a scientific community dedicated to promoting openness and reproducibility in musculoskeletal imaging, image processing, and computational modelling. In this perspective paper, we outline the motivations for conducting transparent research and provide practical guidelines to implement it. We start with defining open and reproducible research and describing the benefits and challenges of working transparently. Next, we redefine the outputs of a computational research study as—ideally—a combination of data, code, and a publication, recommend a folder and file structure that reflects these three study outcomes, and describe how to maintain and update such a structure during the study and at study publication. Finally, we emphasize that working in an open and reproducible manner is a learning process and the best way to acquire the necessary competencies is simply to start. Lay summary: The ORMIR community promotes openness and reproducibility in musculoskeletal imaging research. In this perspective paper, we explain why transparency matters and recommend how to conduct a computational study in an open and reproducible manner focusing on its three outputs: data, code, and publication. Finally, we highlight that the best way to learn these practices is simply to start.
- Open Access
- 3 January 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 196, 112630
Quantification of bone microarchitecture and strength with photon-counting detector CT at different radiation doses: an ex-vivo and in-vivo comparison with HR-pQCT
- 3 January 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 196, 112630
Open AccessQuantification of bone microarchitecture and strength with photon-counting detector CT at different radiation doses: an ex-vivo and in-vivo comparison with HR-pQCT
- Open Access
- 10 February 2023
- Published by Springer Nature in Calcified Tissue International
- Vol. 112 (5) , 621-627
Bone Microarchitecture and Strength Changes During Teriparatide and Zoledronic Acid Treatment in a Patient with Pregnancy and Lactation-Associated Osteoporosis with Multiple Vertebral Fractures
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare form of osteoporosis, of which the pathogenesis and best treatment options are unclear. In this report, we describe the case of a 34-year old woman diagnosed with severe osteoporosis and multiple vertebral fractures after her first pregnancy, who was subsequently treated with teriparatide (TPTD) and zoledronic acid (ZA). We describe the clinical features, imaging examination, and genetic analysis. Substantial improvements were observed in areal and volumetric bone mineral density (BMD), microarchitecture, and strength between 7 and 40 months postpartum as assessed by dual-energy X-ray absorptiometry at the total hip and spine and by high-resolution peripheral quantitative CT at the distal radius and tibiae. At the hip, spine, and distal radius, these improvements were mainly enabled by treatment with TPTD and ZA, while at the distal tibiae, physiological recovery and postpartum physiotherapy due to leg pain after stumbling may have played a major role. Additionally, the findings show that, despite the improvements, BMD, microarchitecture, and strength remained severely impaired in comparison with healthy age- and gender-matched controls at 40 months postpartum. Genetic analysis showed no monogenic cause for osteoporosis, and it is suggested that PLO in this woman could have a polygenic origin with possible susceptibility based on familiar occurrence of osteoporosis.
- 10 February 2023
- Published by Springer Nature in Calcified Tissue International
- Vol. 112 (5) , 621-627
Open AccessBone Microarchitecture and Strength Changes During Teriparatide and Zoledronic Acid Treatment in a Patient with Pregnancy and Lactation-Associated Osteoporosis with Multiple Vertebral Fractures
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare form of osteoporosis, of which the pathogenesis and best treatment options are unclear. In this report, we describe the case of a 34-year old woman diagnosed with severe osteoporosis and multiple vertebral fractures after her first pregnancy, who was subsequently treated with teriparatide (TPTD) and zoledronic acid (ZA). We describe the clinical features, imaging examination, and genetic analysis. Substantial improvements were observed in areal and volumetric bone mineral density (BMD), microarchitecture, and strength between 7 and 40 months postpartum as assessed by dual-energy X-ray absorptiometry at the total hip and spine and by high-resolution peripheral quantitative CT at the distal radius and tibiae. At the hip, spine, and distal radius, these improvements were mainly enabled by treatment with TPTD and ZA, while at the distal tibiae, physiological recovery and postpartum physiotherapy due to leg pain after stumbling may have played a major role. Additionally, the findings show that, despite the improvements, BMD, microarchitecture, and strength remained severely impaired in comparison with healthy age- and gender-matched controls at 40 months postpartum. Genetic analysis showed no monogenic cause for osteoporosis, and it is suggested that PLO in this woman could have a polygenic origin with possible susceptibility based on familiar occurrence of osteoporosis.
- Open Access
- 19 April 2022
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (6) , 1136-1146
Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
In a randomized clinical trial in patients initiating glucocorticoid therapy (GC-I) or on long-term therapy (GC-C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than daily risedronate. The aim of this study was to evaluate the effects of denosumab compared with risedronate on bone strength and microarchitecture measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) in GC-I and GC-C. A subset of 110 patients had high-resolution peripheral quantitative computed tomography (HR-pQCT) scans of the distal radius and tibia at baseline and at 12 and 24 months. Cortical and trabecular microarchitecture were assessed with standard analyses and failure load (FL) with micro-finite element analysis. At the radius at 24 months, FL remained unchanged with denosumab and significantly decreased with risedronate in GC-I (−4.1%, 95% confidence interval [CI] −6.4, −1.8) and, in GC-C, it significantly increased with denosumab (4.3%, 95% CI 2.1, 6.4) and remained unchanged with risedronate. Consequently, FL was significantly higher with denosumab than with risedronate in GC-I (5.6%, 95% CI 2.4, 8.7, p < 0.001) and in GC-C (4.1%, 95% CI 1.1, 7.2, p = 0.011). We also found significant differences between denosumab and risedronate in percentage changes in cortical and trabecular microarchitectural parameters in GC-I and GC-C. Similar results were found at the tibia. To conclude, this HR-pQCT study shows that denosumab is superior to risedronate in terms of preventing FL loss at the distal radius and tibia in GC-I and in increasing FL at the radius in GC-C, based on significant differences in changes in the cortical and trabecular bone compartments between treatment groups in GC-I and GC-C. These results suggest that denosumab could be a useful therapeutic option in patients initiating GC therapy or on long-term GC therapy and may contribute to treatment decisions in this patient population. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- 19 April 2022
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (6) , 1136-1146
Open AccessEffect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
In a randomized clinical trial in patients initiating glucocorticoid therapy (GC-I) or on long-term therapy (GC-C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than daily risedronate. The aim of this study was to evaluate the effects of denosumab compared with risedronate on bone strength and microarchitecture measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) in GC-I and GC-C. A subset of 110 patients had high-resolution peripheral quantitative computed tomography (HR-pQCT) scans of the distal radius and tibia at baseline and at 12 and 24 months. Cortical and trabecular microarchitecture were assessed with standard analyses and failure load (FL) with micro-finite element analysis. At the radius at 24 months, FL remained unchanged with denosumab and significantly decreased with risedronate in GC-I (−4.1%, 95% confidence interval [CI] −6.4, −1.8) and, in GC-C, it significantly increased with denosumab (4.3%, 95% CI 2.1, 6.4) and remained unchanged with risedronate. Consequently, FL was significantly higher with denosumab than with risedronate in GC-I (5.6%, 95% CI 2.4, 8.7, p < 0.001) and in GC-C (4.1%, 95% CI 1.1, 7.2, p = 0.011). We also found significant differences between denosumab and risedronate in percentage changes in cortical and trabecular microarchitectural parameters in GC-I and GC-C. Similar results were found at the tibia. To conclude, this HR-pQCT study shows that denosumab is superior to risedronate in terms of preventing FL loss at the distal radius and tibia in GC-I and in increasing FL at the radius in GC-C, based on significant differences in changes in the cortical and trabecular bone compartments between treatment groups in GC-I and GC-C. These results suggest that denosumab could be a useful therapeutic option in patients initiating GC therapy or on long-term GC therapy and may contribute to treatment decisions in this patient population. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- 20 October 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (24) , 2138-2145
Improved Detection of Scaphoid Fractures with High-Resolution Peripheral Quantitative CT Compared with Conventional CT
Background: Computed tomography (CT), magnetic resonance imaging, and bone scintigraphy are second-line imaging techniques that are frequently used for the evaluation of patients with a clinically suspected scaphoid fracture. However, as a result of varying diagnostic performance results, no true reference standard exists for scaphoid fracture diagnosis. We hypothesized that the use of high-resolution peripheral quantitative CT (HR-pQCT) in patients with a clinically suspected scaphoid fracture could improve scaphoid fracture detection compared with conventional CT in the clinical setting. Methods: The present study included 91 consecutive patients (≥18 years of age) who presented to the emergency department with a clinically suspected scaphoid fracture between December 2017 and October 2018. All patients were clinically reassessed within 14 days after first presentation, followed by CT and HR-pQCT. If a scaphoid fracture was present, the fracture type was determined according to the Herbert classification system and correlation between CT and HR-pQCT was estimated with use of the Kendall W statistic or coefficient of concordance (W) (the closer to 1, the higher the correlation). Results: The cohort included 45 men and 46 women with a median age of 52 years (interquartile range, 29 to 67 years). HR-pQCT revealed a scaphoid fracture in 24 patients (26%), whereas CT revealed a scaphoid fracture in 15 patients (16%). Patients with a scaphoid fracture were younger and more often male. The correlation between CT and HR-pQCT was high for scaphoid fracture type according to the Herbert classification system (W = 0.793; 95% confidence interval [CI], 0.57 to 0.91; p < 0.001) and very high for scaphoid fracture location (W = 0.955; 95%, CI 0.90 to 0.98; p < 0.001). Conclusions: In the present study, the number of patients diagnosed with a scaphoid fracture was 60% higher when using HR-pQCT as compared with CT. These findings imply that a substantial proportion of fractures—in this study, more than one-third—will be missed by the current application of CT scanning in patients with a clinically suspected scaphoid fracture. Level of Evidence: Diagnostic Level II. See Instructions for Authors for a complete description of levels of evidence.
- 20 October 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (24) , 2138-2145
Improved Detection of Scaphoid Fractures with High-Resolution Peripheral Quantitative CT Compared with Conventional CT
Background: Computed tomography (CT), magnetic resonance imaging, and bone scintigraphy are second-line imaging techniques that are frequently used for the evaluation of patients with a clinically suspected scaphoid fracture. However, as a result of varying diagnostic performance results, no true reference standard exists for scaphoid fracture diagnosis. We hypothesized that the use of high-resolution peripheral quantitative CT (HR-pQCT) in patients with a clinically suspected scaphoid fracture could improve scaphoid fracture detection compared with conventional CT in the clinical setting. Methods: The present study included 91 consecutive patients (≥18 years of age) who presented to the emergency department with a clinically suspected scaphoid fracture between December 2017 and October 2018. All patients were clinically reassessed within 14 days after first presentation, followed by CT and HR-pQCT. If a scaphoid fracture was present, the fracture type was determined according to the Herbert classification system and correlation between CT and HR-pQCT was estimated with use of the Kendall W statistic or coefficient of concordance (W) (the closer to 1, the higher the correlation). Results: The cohort included 45 men and 46 women with a median age of 52 years (interquartile range, 29 to 67 years). HR-pQCT revealed a scaphoid fracture in 24 patients (26%), whereas CT revealed a scaphoid fracture in 15 patients (16%). Patients with a scaphoid fracture were younger and more often male. The correlation between CT and HR-pQCT was high for scaphoid fracture type according to the Herbert classification system (W = 0.793; 95% confidence interval [CI], 0.57 to 0.91; p < 0.001) and very high for scaphoid fracture location (W = 0.955; 95%, CI 0.90 to 0.98; p < 0.001). Conclusions: In the present study, the number of patients diagnosed with a scaphoid fracture was 60% higher when using HR-pQCT as compared with CT. These findings imply that a substantial proportion of fractures—in this study, more than one-third—will be missed by the current application of CT scanning in patients with a clinically suspected scaphoid fracture. Level of Evidence: Diagnostic Level II. See Instructions for Authors for a complete description of levels of evidence.